Pfizer (PFE) is a leading drug manufacturers - general business based in the US. It opened the day at $22.65 after a previous close of $22.83. During the day the price has varied from a low of $22.45 to a high of $22.85. The latest price was $22.83 (25 minute delay). Pfizer is listed on the NYSE and employs 81,000 staff. All prices are listed in US Dollars.
May 12, 2025: US pharma stocks rose in response to US President Donald Trump's pledge to bring down the price of drugs in the US.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $20.53 - $29.98 |
|---|---|
| 50-day moving average | $23.98 |
| 200-day moving average | $26.62 |
| Wall St. target price | $29.50 |
| PE ratio | 16.4245 |
| Dividend yield | $1.69 (7.61%) |
| Earnings per share (TTM) | $1.39 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $22.83 from 2025-05-16
| 1 week (2025-05-09) | 2.47% |
|---|---|
| 1 month (2025-04-17) | 3.12% |
| 3 months (2025-02-19) | -11.82% |
| 6 months (2024-11-19) | -9.04% |
| 1 year (2024-05-17) | -20.29% |
|---|---|
| 2 years (2023-05-18) | -29.50% |
| 3 years (2022-05-18) | 43.152 |
| 5 years (2020-05-18) | 28.7183 |
Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Pfizer shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5791. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $23.3 billion.
The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $62.5 billion |
|---|---|
| Operating margin TTM | 35.17% |
| Gross profit TTM | $46.5 billion |
| Return on assets TTM | 4.79% |
| Return on equity TTM | 8.62% |
| Profit margin | 12.62% |
| Book value | $15.89 |
| Market Capitalization | $129.8 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 33.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 12/31/2018) is pretty weak – landing it in it in the 60th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 7/100
Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 18.47/100
Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.68/100
Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.
Pfizer Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 33.15 |
|---|---|
| Total ESG percentile | 60 |
| Environmental score | 7 |
| Environmental score percentile | 6 |
| Social score | 18.47 |
| Social score percentile | 6 |
| Governance score | 13.68 |
| Governance score percentile | 6 |
| Level of controversy | 3 |
Dividend payout ratio: 52.96% of net profits
Recently Pfizer has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.69 per share.
Pfizer's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Pfizer's most recent dividend payout was on 12 June 2025. The latest dividend was paid out to all shareholders who bought their shares by 8 May 2025 (the "ex-dividend date").
Pfizer's shares were split on a 1054:1000 basis on 16 November 2020 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer shares – just the quantity. However, indirectly, the new 5.1% lower share price could have impacted the market appetite for Pfizer shares which in turn could have impacted Pfizer's share price.
Over the last 12 months, Pfizer's shares have ranged in value from as little as $20.5284 up to $29.9806. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.502. This would suggest that Pfizer's shares are less volatile than average (for this exchange).
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.